- Home
- SAND vs IMVT Comparison
SAND vs IMVT Comparison
Compare SAND & IMVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SAND
- IMVT
- Stock Information
- Founded
- SAND 2007
- IMVT 2018
- Country
- SAND Canada
- IMVT United States
- Employees
- SAND N/A
- IMVT N/A
- Industry
- SAND
- IMVT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SAND
- IMVT Health Care
- Exchange
- SAND NYSE
- IMVT Nasdaq
- Market Cap
- SAND 2.4B
- IMVT 2.7B
- IPO Year
- SAND N/A
- IMVT N/A
- Fundamental
- Price
- SAND $9.87
- IMVT $18.12
- Analyst Decision
- SAND Buy
- IMVT Buy
- Analyst Count
- SAND 3
- IMVT 10
- Target Price
- SAND $9.00
- IMVT $40.14
- AVG Volume (30 Days)
- SAND 8.1M
- IMVT 1.3M
- Earning Date
- SAND 08-07-2025
- IMVT 08-05-2025
- Dividend Yield
- SAND 0.64%
- IMVT N/A
- EPS Growth
- SAND 32.83
- IMVT N/A
- EPS
- SAND 0.10
- IMVT N/A
- Revenue
- SAND $183,537,000.00
- IMVT N/A
- Revenue This Year
- SAND $17.55
- IMVT N/A
- Revenue Next Year
- SAND $10.62
- IMVT N/A
- P/E Ratio
- SAND $101.00
- IMVT N/A
- Revenue Growth
- SAND 2.84
- IMVT N/A
- 52 Week Low
- SAND $4.92
- IMVT $12.72
- 52 Week High
- SAND $10.44
- IMVT $34.47
- Technical
- Relative Strength Index (RSI)
- SAND 61.17
- IMVT 68.50
- Support Level
- SAND $9.67
- IMVT $16.88
- Resistance Level
- SAND $10.44
- IMVT $17.10
- Average True Range (ATR)
- SAND 0.33
- IMVT 0.71
- MACD
- SAND 0.03
- IMVT 0.16
- Stochastic Oscillator
- SAND 62.97
- IMVT 99.65
About SAND SANDSTORM GOLD LIMITED
Sandstorm Gold Ltd provides financing to companies engaged in gold mining through the gold stream and royalty. Geographically, the company has operational footprints in North America, South & Central America, Africa, and Asia & Australia. The firm's royalties include Hod Maden, Santa Elena, Chapada, Platreef, Greenstone, and Cerro Moro.
About IMVT Immunovant Inc.
Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The company operates in a single operating segment, which includes all activities related to the research, development and manufacturing of its product candidates.